{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+placebo",
    "query": {
      "intervention": "Oral placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10190,
    "total_pages": 1019,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T19:10:33.237Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04365400",
      "title": "Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertriglyceridemia",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "DS102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Afimmune",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2020-10-13",
      "completion_date": "2022-05-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 32,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Huntington Park, California + 24 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04365400"
    },
    {
      "nct_id": "NCT00386971",
      "title": "Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperlipidemia",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "L-carnitine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2006-10",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00386971"
    },
    {
      "nct_id": "NCT00744016",
      "title": "Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Granulated mesalamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2004-12",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 1,
      "location_summary": "Bristol, Connecticut",
      "locations": [
        {
          "city": "Bristol",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00744016"
    },
    {
      "nct_id": "NCT04301284",
      "title": "Study of CAD-1883 for Spinocerebellar Ataxia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinocerebellar Ataxias",
        "Spinocerebellar Ataxia Type 1",
        "Spinocerebellar Ataxia Type 2",
        "Spinocerebellar Ataxia Type 3",
        "Spinocerebellar Ataxia Type 6",
        "Spinocerebellar Ataxia Type 7",
        "Spinocerebellar Ataxia Type 8",
        "Spinocerebellar Ataxia Type 10",
        "Spinocerebellar Ataxia Type 17",
        "ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1"
      ],
      "interventions": [
        {
          "name": "CAD-1883",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cadent Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-06",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2021-04-08",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 6,
      "location_summary": "Long Beach, California • Los Angeles, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04301284"
    },
    {
      "nct_id": "NCT02294058",
      "title": "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo to ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo to interferon beta-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1346,
      "start_date": "2014-12-03",
      "completion_date": "2016-12-22",
      "has_results": true,
      "last_update_posted_date": "2020-11-25",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 40,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02294058"
    },
    {
      "nct_id": "NCT04025255",
      "title": "The Memory and Cognitive Performance Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cognitive Function",
        "Memory",
        "Brain Health"
      ],
      "interventions": [
        {
          "name": "Braini",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Vita Naturel, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 74,
      "start_date": "2019-10-01",
      "completion_date": "2020-04-30",
      "has_results": false,
      "last_update_posted_date": "2022-11-21",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 1,
      "location_summary": "Asheville, North Carolina",
      "locations": [
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04025255"
    },
    {
      "nct_id": "NCT06274385",
      "title": "The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nutraceuticals"
      ],
      "interventions": [
        {
          "name": "Betalain-rich concentrate (AltRed)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Drexel University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-03-06",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06274385"
    },
    {
      "nct_id": "NCT01349725",
      "title": "A Safety Study of ARRY-502 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ARRY-502",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-05",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349725"
    },
    {
      "nct_id": "NCT07215884",
      "title": "Dopamine and Sensorimotor Function in Stuttering",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stuttering, Adult"
      ],
      "interventions": [
        {
          "name": "Aripiprazole 10 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-09-30",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215884"
    },
    {
      "nct_id": "NCT02507284",
      "title": "Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Irritable Mood",
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "SRX246",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Azevan Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2016-05-10",
      "completion_date": "2018-12-21",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-09-10T19:10:33.237Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02507284"
    }
  ]
}